NEWS
Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals (TSX/NASDAQ: EPRX) announced positive data from the fifth cohort of its RESOLVE Phase 1b/2a trial for EP-104GI in treating Eosinophilic Esophagitis (EoE). Key highlights include: one patient achieving complete histological remission at 12 weeks, consistent improvement in patient-reported outcomes, and the largest average reduction in symptom scores observed in the fourth cohort at 24 weeks. The fifth cohort showed the greatest percentage change in histology scores to date, with clear dose response across Cohorts 3 to 5. No serious adverse events were reported, and Cohort 6 is fully enrolled with data expected in Q1 2025.
Eupraxia Pharmaceuticals (TSX/NASDAQ: EPRX) announced positive data from the fifth cohort of its RESOLVE Phase 1b/2a trial for EP-104GI in treating Eosinophilic Esophagitis (EoE). Key highlights include: one patient achieving complete histological remission at 12 weeks, consistent improvement in patient-reported outcomes, and the largest average reduction in symptom scores observed in the fourth cohort at 24 weeks. The fifth cohort showed the greatest percentage change in histology scores to date, with clear dose response across Cohorts 3 to 5. No serious adverse events were reported, and Cohort 6 is fully enrolled with data expected in Q1 2025.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
2880Followers
108Following
30KVisitors
Follow